Trial of zanzalintinib with immunotherapy for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced or metastatic clear cell kidney cancer.
- You must have taken an immunotherapy drug like nivolumab or pembrolizumab after surgery and your cancer got worse during or after that treatment.
- You cannot have had any other cancer treatments after that immunotherapy except for this trial.
- Your cancer must be measurable on scans.
- Your blood and organ function must be good enough based on routine lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests two drugs (zanzalintinib and MO-03) together to treat advanced kidney cancer that has grown despite previous immunotherapy treatment. The goal is to slow or stop cancer growth in patients who have already tried other treatments.
This trial tests a combination of two drugs (tivozanib and nivolumab) for people with advanced kidney cancer that is not clear cell type. It aims to see if this drug pair can shrink or slow the cancer.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This trial tests two drugs—zanzalintinib and nivolumab—given before surgery to shrink advanced or hard-to-remove kidney tumors. The goal is to make the tumor easier to remove and improve outcomes.
Hear when a new Advanced Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.